What This Is: A monthly snapshot of publicly advertised starting prices across the compounded GLP-1 telehealth market. Prices are based on provider websites and enrollment pages as of mid-July 2026. Always verify current pricing directly — rates change without notice.
The compounded GLP-1 market in mid-2026 is a moving target. Providers adjust pricing monthly, launch intro offers that disappear without warning, and bundle (or unbundle) consultation fees in ways that make apples-to-apples comparison genuinely difficult. This price index cuts through the noise with a straightforward snapshot: what does each provider actually charge per month, at the starting dose, as of right now?
We update this index monthly. Prices reflect the lowest publicly advertised monthly rate for new patients at the starting dose tier. This is the "walk in the door" price — not the rate after titrating to higher doses, which costs more at most providers. The dose-adjusted cost breakdown is covered in our separate dose creep analysis.
Injectable Compounded Semaglutide: The Starting-Dose Tier
Injectable compounded semaglutide remains the most competitive segment, with starting prices ranging from approximately $99/month at the budget end to $299/month at the premium tier. The median price across providers we track has settled around $175 to $199/month — a slight decrease from January 2026, when the median was closer to $210.
Several forces are driving prices down:
- Market competition: More providers entering the compounded GLP-1 space means more price competition for new patients, particularly at the starting dose where acquisition economics dominate pricing strategy
- API cost declines: Semaglutide active pharmaceutical ingredient costs have decreased as more registered manufacturers enter the market and scale production
- Patient retention focus: Providers are learning that lower starting prices improve retention through the titration phase, even if they recoup margin at higher doses
⚠️ Important Context: "Starting price" is not "all-in cost." Some providers include consultation fees, shipping, and supplies in the monthly price. Others bill these separately. Our per-provider breakdowns identify what's bundled and what's extra. The provider cards at the bottom of this article link to current enrollment pages where you can verify the complete cost structure.
Injectable Compounded Tirzepatide: The Dual-Agonist Premium
Tirzepatide (the molecule in Zepbound and Mounjaro) commands a premium over semaglutide at virtually every provider. The typical markup ranges from $25 to $100 per month at equivalent dose levels. This premium reflects higher API costs for tirzepatide and the clinical positioning of tirzepatide as a "next-level" treatment option.
Starting prices for injectable compounded tirzepatide generally range from $199 to $350/month across the providers we track. The competitive sweet spot appears to be settling around $225 to $250/month — below brand-name Zepbound pricing but above the cheapest semaglutide options.
Oral and Sublingual Formats: The Needle-Free Tier
Oral compounded tirzepatide tablets and sublingual formulations represent the newest pricing tier, with monthly costs ranging from approximately $149 to $225/month. The format premium (over injectable) is smaller than many patients expect — in some cases, oral formats are actually cheaper than their injectable equivalents at the same provider, because the lower bioavailability requires less API per dose and providers are pricing aggressively to drive adoption of this newer format.
Brand-Name Reference Prices
For context, here's where brand-name GLP-1 medications sit without insurance as of mid-2026:
- Wegovy (semaglutide): Approximately $1,300/month at list price, with manufacturer savings programs potentially reducing out-of-pocket costs for eligible patients
- Zepbound (tirzepatide): Approximately $1,050/month at list price, with Eli Lilly's savings card programs for commercial insurance patients
- Ozempic (semaglutide, diabetes indication): Approximately $900–$1,000/month without insurance
The gap between brand-name and compounded pricing — roughly 85% to 95% savings — remains the primary driver of the compounded GLP-1 market.
What Moves Prices Month to Month
The factors that shift this index between updates:
- New provider launches: Startups entering the market typically launch at aggressive pricing to build patient volume, temporarily pulling the market average down
- Seasonal promotions: Many providers run promotional pricing tied to New Year's resolutions (January), summer body goals (May–June), and back-to-school (August). The August index captures the early-fall promotional cycle.
- Regulatory changes: FDA shortage designations, compounding regulation updates, and 503B facility decisions can affect supply dynamics and, consequently, pricing
- API market shifts: Changes in semaglutide or tirzepatide API pricing from pharmaceutical ingredient manufacturers ripple through to patient-facing costs within 2 to 3 months
- Provider exits: When a provider leaves the market or pauses enrollment, their former patients redistribute to remaining providers, reducing competitive pressure and potentially allowing price increases
How to Use This Index
This price index is a starting point, not a final answer. When comparing providers, consider:
- Total first-month cost: Including any enrollment fee, consultation fee, lab work, shipping, and supplies that aren't included in the advertised monthly rate
- Dose-adjusted trajectory: What the price becomes at 1.0 mg, 1.7 mg, and 2.4 mg — some providers maintain flat pricing across doses while others increase substantially
- Commitment requirements: Monthly flexibility vs. quarterly billing vs. annual plans — and the cancellation terms for each
- Pharmacy quality: The cheapest price isn't the best value if it comes from a pharmacy with quality concerns. Accreditation status, testing practices, and regulatory history matter.
Methodology: Prices are sourced from provider websites, enrollment pages, and direct verification where possible. We do not include promotional codes or limited-time offers unless they're prominently advertised on the provider's homepage. "Starting price" reflects the lowest available monthly rate for the lowest dose tier at standard (non-promotional) pricing. This index is updated in the first week of each month.
Frequently Asked Questions
Why do prices vary so much between providers?
The spread reflects differences in pharmacy partnerships (different pharmacies have different cost structures), bundled vs. unbundled services, margin targets, and patient acquisition strategy. A provider charging $149/month may be subsidizing early losses with higher maintenance-dose pricing or lower service levels. A provider at $249/month may include consultation fees, lab work, and dedicated provider access that others charge separately.
Is the cheapest option always the best deal?
Not necessarily. The lowest starting price may come with higher prices at maintenance doses, mandatory quarterly billing, limited cancellation flexibility, or fewer included services. Total cost of ownership over 6 to 12 months is a more meaningful comparison than month-1 price alone.
How often do prices change?
Most providers adjust pricing quarterly. Some change monthly during high-competition periods. Promotional pricing can appear and disappear within days. We recommend verifying current rates on the provider's website before enrolling, regardless of when this index was last updated.
Compare GLP-1 Prices Side by Side
Every provider below offers compounded GLP-1 medications from licensed U.S. pharmacies. Pricing verified as of July 17, 2026 — always confirm current rates before enrolling.